Jonathan Ellermeier

Biochemistry, Genetics and Molecular Biology · Life Sciences

3h-index340citations24works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(19), Nanoplatforms for cancer theranostics(11), Immune cells in cancer(9), interferon and immune responses(9), Phagocytosis and Immune Regulation(7)

Publications24 total

Supplementary Table 1 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 5 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Table 1 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 4 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Data from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Data from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 4 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 3 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 5 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 2 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure Legend from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 2 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 3 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 1 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure 1 from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Supplementary Figure Legend from Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
2023Open Access
Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
Cancer Research·2013· 146 cited
Immuntherapie des Pankreaskarzinoms : Mechanismen und Strategien zur Durchbrechung tumorinduzierter Immunsuppression
2013· 1 cited
Treatment of pancreatic cancer with bifunctional siRNA silencing TGF-b and activating RIG-I (74.13)
The Journal of Immunology·2012· 2 cited
Chemoimmuntherapie des Pankreaskarzinoms mit bifunktioneller siRNA gegen TGFβ1
Zeitschrift für Gastroenterologie·2011
page 1 of 2Next →

Frequent Co-authors

Stefan Endres(23), Max Schnurr(22), Jiwu Wei(19), Sabine Hoves(19), Peter Duewell(18), Mareike R. Stieg(18), Tina Adunka(17), Daniel Noerenberg(17), Hans‐Joachim Anders(17), Doris Mayr(17), Hendrik Poeck(17), Gunther Hartmann(17), P Düwell(4), David Anz(1), Wolfgang P. Mueller(1), Michaela Golić(1), Wolfgang G. Kunz(1), Moritz Rapp(1), Viktor H. Koelzer(1), Joachim W. Ellwart(1)